MONTREAL, QUEBEC -- (MARKET WIRE) -- August 17, 2006 -- Ecopia BioSciences Inc. (TSX: EIA) will unveil new data at the 12th Salk Institute Meeting on Protein Phosphorylation and Cell Signaling, starting tomorrow in La Jolla, California. These data describe supporting evidence that ECO-4601 is a potent inhibitor of the RAS-mitogen-activated protein kinase (MAPK) pathway, an important target pathway for anticancer therapies. The scientific community recognizes this pathway as the most strategic target in the fight against cancer therefore, anticancer agents inhibiting this pathway are currently the most valued by the industry. ECO-4601 has been shown to inhibit this pathway at a strategic point allowing for a broad action towards many types of cancer such as brain, pancreatic, lung, colorectal, ovarian, breast and prostate.
